Scarica l'app Stockscreener
3.63
1.68%
0.06
Dopo l'orario di chiusura:
3.63
Precedente Chiudi:
$3.57
Aprire:
$3.6142
Volume 24 ore:
931
Relative Volume:
0.01
Capitalizzazione di mercato:
$5.60M
Reddito:
$2.54M
Utile/perdita netta:
$-4.13M
Rapporto P/E:
-1.32
EPS:
-2.75
Flusso di cassa netto:
$-4.11M
1 W Prestazione:
+0.00%
1M Prestazione:
+32.48%
6M Prestazione:
-15.58%
1 anno Prestazione:
-14.59%
Intervallo 1D:
$3.6142
$3.6999
Intervallo di 1 settimana:
$3.4473
$3.95
Portata 52W:
$2.20
$5.2683
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Nome
Xenetic Biosciences Inc
Settore
Industria
Telefono
781-778-7720
Indirizzo
945 CONCORD ST., FRAMINGHAM, MA
Confronta XBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.63 | 5.51M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-01-08 | Iniziato | Maxim Group | Buy |
Xenetic Biosciences Inc Borsa (XBIO) Ultime notizie
Xenetic Biosciences Inc. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Great Falls Tribune
Xenetic expands DNase-I collaboration with Scripps Research By Investing.com - Investing.com South Africa
Revolutionary Cancer Treatment: Xenetic and Scripps Advance DNase-CAR-T Therapy for Lymphoma and Leukemia - Stock Titan
What analysts say about Xenetic Biosciences Inc. stockRobust investment performance - jammulinksnews.com
What drives Xenetic Biosciences Inc. stock priceExceptional market positioning - jammulinksnews.com
Is Xenetic Biosciences Inc. a good long term investmentConsistently exceptional gains - jammulinksnews.com
Why Xenetic Biosciences Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
What makes Xenetic Biosciences Inc. stock price move sharplyFree Exclusive Investment Tips - Newser
How Xenetic Biosciences Inc. stock performs during market volatilityOptimized Return Investment Picks - Newser
Xenetic Biosciences (NASDAQ:XBIO) Shares Down 8% – What’s Next? - Defense World
Head to Head Comparison: Xenetic Biosciences (NASDAQ:XBIO) versus Vaxart (NASDAQ:VXRT) - Defense World
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C - The Holland Sentinel
New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Great Falls Tribune
North Shore Uranium Engages Investing News Network - Great Falls Tribune
LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum - Great Falls Tribune
Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock - Great Falls Tribune
Groundbreaking Pancreatic Cancer Trial Launches: DNase I Combined With FOLFIRINOX in Advanced Cases - Stock Titan
Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth - Great Falls Tribune
Xenetic Biosciences’ 13.5% Surge: What’s Driving the Unexplained Rally? - AInvest
Pre-market Movers: NKTR, INM, IBIO, IBO... - RTTNews
Why Did Cyclacel Pharmaceuticals Inc. (CYCC) Soar 13.92%? - AInvest
Xenetic Biosciences Reports Improved Q1 2025 Results - TipRanks
Xenetic Biosciences Inc Azioni (XBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):